BiotechTube

ACE-083 + ACE-083 or placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy

Conditions

Facioscapulohumeral Muscular Dystrophy

Trial Timeline

Nov 1, 2016 → Oct 9, 2019

NCT ID
NCT02927080

About ACE-083 + ACE-083 or placebo

ACE-083 + ACE-083 or placebo is a phase 2 stage product being developed by Merck for Facioscapulohumeral Muscular Dystrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02927080. Target conditions include Facioscapulohumeral Muscular Dystrophy.

What happened to similar drugs?

0 of 2 similar drugs in Facioscapulohumeral Muscular Dystrophy were approved

Approved (0) Terminated (1) Active (1)
🔄AOC-1020 + PlaceboAvidity BiosciencesPhase 3
❌Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02927080Phase 2Terminated

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
ACE-083MerckPhase 2
27
Placebo + RO7204239RochePhase 2
39
AOC-1020 + PlaceboAvidity BiosciencesPhase 3
44
Apitegromab + PlaceboScholar Rock HoldingPhase 2
39
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
25
Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3
22
LosmapimodFulcrum TherapeuticsPhase 2
17
LosmapimodFulcrum TherapeuticsPhase 2
17
ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22
Placebo + ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22